Philip Loury, University of California San Diego
The treatment of the Human Immunodeficiency Virus strain HIV-1 requires close monitoring of patient viral load in order to verify that treatment is successfully inhibiting replication of the retrovirus. The impact of HIV drug resistance (DR) following the initiation of first-line antiretroviral therapy (ART) is an emerging issue of critical importance to the success of HIV treatment in developing countries. Hospitals in developing nations cannot afford such testing or lack personnel and equipment for proper sample preparation and analysis. In order to confront this challenge, the Engineering World Health chapter at UCSD has launched a project to design a cost-effective point-of-care solution to screen HIV patients for ART drug resistance, thus enabling hospitals and clinics in the developing world to better diagnose and appropriately treat their patients.
Know Before You Go: 2016 ISPE Biopharmaceutical Manufacturing Conference
Friday, 02 Dec 2016 17.12
Sights & Bites of San Francisco – 2016 ISPE Biopharmaceutical Manufacturing Conference
Thursday, 01 Dec 2016 13.12
ISPE Baseline® Guide: Oral Solid Dosage Forms (Third Edition)
Wednesday, 30 Nov 2016 18.11